Aficamten and Cardiopulmonary Exercise Test Performance

Overview of attention for article published in JAMA Cardiology, November 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

news: 6 news outlets
blogs: 2 blogs
twitter: 16 X users

patent: 1 patent
facebook: 1 Facebook page

Readers on

mendeley: 41 Mendeley

So far, Altmetric has seen 19 X posts from 16 X users, with an upper bound of 147,612 followers.

RT @drbennisahmed: Aficamten and Cardiopulmonary Exercise Test Performance A Substudy of the SEQUOIA-HCM Randomized Clinical Trial Aficamt…

RT @JAMACardio: This prespecified analysis of the SEQUOIA-HCM randomized clinical trial found that aficamten treatment improved a broad ran…

RT @drbennisahmed: Aficamten and Cardiopulmonary Exercise Test Performance A Substudy of the SEQUOIA-HCM Randomized Clinical Trial Aficamt…

Aficamten and Cardiopulmonary Exercise Test Performance A Substudy of the SEQUOIA-HCM Randomized Clinical Trial Aficamten treatment improves several exercise performance measures in patients with obstructive HCM https://t.co/wMv9qqeJAm https://t.co/h9…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 15 additional X posts.